PLK
Os inibidores de quinases Polo-like (PLK) têm como alvo as PLKs, uma família de quinases serina/treonina essenciais para várias fases da divisão celular, incluindo entrada na mitose, montagem do fuso e citocinese. As PLKs são críticas para a execução adequada do ciclo celular, e sua desregulação é frequentemente associada ao câncer. Inibir as PLKs pode induzir parada do ciclo celular e apoptose em células cancerígenas, tornando esses inibidores ferramentas importantes na pesquisa e terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PLK de alta qualidade para apoiar sua pesquisa em mitose, controle do ciclo celular e oncologia.
Foram encontrados 29 produtos para "PLK".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
PROTAC PLK1 Degrader-3
CAS:PROTACPLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader that operates via the N-deglycosylation pathway, with a dissociation constant (Kd) of 2.2 μM. Its cell permeability is limited, requiring higher concentrations to achieve a notable degradation effect. PROTACPLK1 Degrader-3 is applicable in research on non-small cell lung cancer.Fórmula:C102H196N57O23PPeso molecular:2620.04PLK1-IN-14
PLK1-IN-14 (Compound Hit-4) is a selective PLK1 inhibitor with an IC50 of 22.61 pM for PLK1, and an IC50 of 0.09 nM for inhibiting the proliferation of DU-145 prostate cancer cells. It is applicable in prostate cancer research.Cor e Forma:Odour SolidPLK1-IN-12
PLK1-IN-12 is a highly selective, orally active PLK1 inhibitor with an IC50 of 20 nM. It demonstrates greater selectivity for PLK1 over PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer efficacy across a wide range of cell lines and is applicable to anti-leukemia research.Cor e Forma:Odour SolidSP27
CAS:SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1].Fórmula:C40H40F2N12O5Pureza:98%Cor e Forma:SolidPeso molecular:806.82RP-1664
CAS:RP-1664,PLK4 inhibitor (IC50=3 nM). Disrupts centriole biogenesis. Antitumor activity in breast cancer, neuroblastoma.Fórmula:C23H24F2N8O2SPureza:99.04%Cor e Forma:SolidPeso molecular:514.55Poloxime
CAS:Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.Fórmula:C10H13NO2Pureza:98%Cor e Forma:SolidPeso molecular:179.22PLK1 Protein, Mouse, Recombinant (His)
PLK1 Protein, Mouse, Recombinant (His) is expressed in Baculovirus insect cells with His tag.Cor e Forma:Lyophilized PowderPeso molecular:70.6 kDa (predicted); 65 kDa (reducing conditions)PLK1 Protein, Human, Recombinant (His)
PLK1 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag.Pureza:96.8%Cor e Forma:Lyophilized PowderPeso molecular:70.5 kDa (predicted); 66 kDa (reducing conditions)PLK1-IN-9
CAS:PLK1-IN-9 (Compound M2), a polo-like kinase 1 (PLK1) inhibitor, targets the PLK proteins modified with peptides 1010pT, cdc25c, and PBIP, exhibiting IC50 values of 1.6, 0.8, and 1.4 μM, respectively. This compound effectively inhibits the proliferation of various cancer cell lines including HeLa, HL60, SNU387/499, and HepG2, demonstrating cytotoxic effects and inducing apoptosis. Additionally, PLK1-IN-9 has been shown to suppress tumor growth in a HepG2 xenograft mouse model.Fórmula:C12H7F3N4O2Peso molecular:296.2048GSK461364
CAS:GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.Fórmula:C27H28F3N5O2SPureza:99% - 99.93%Cor e Forma:SolidPeso molecular:543.604Poloxin
CAS:Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).Fórmula:C18H19NO3Pureza:98.17%Cor e Forma:SolidPeso molecular:297.3484SBE13
CAS:SBE13 is a highly selective PLK1 inhibitor (IC₅₀=200 pM), a type II inhibitor with anti-tumor activity.Fórmula:C24H27ClN2O4Pureza:99.59%Cor e Forma:SolidPeso molecular:442.9355-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE
CAS:5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.Fórmula:C8H13N3SPureza:99.03%Cor e Forma:SolidPeso molecular:183.274HMN-214
CAS:HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.Fórmula:C22H20N2O5SPureza:98% - >99.99%Cor e Forma:SolidPeso molecular:424.47TAK-960
CAS:TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.Fórmula:C27H34F3N7O3Pureza:97.06%Cor e Forma:White SolidPeso molecular:561.60Ro3280
CAS:Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).Fórmula:C27H35F2N7O3Pureza:97.76% - >99.99%Cor e Forma:SolidPeso molecular:543.6087MLN0905
CAS:MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).Fórmula:C24H25F3N6SPureza:98% - 99.92%Cor e Forma:Yellow SolidPeso molecular:486.556(1E)-CFI-400437 dihydrochloride
CAS:(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.Fórmula:C29H30Cl2N6O2Pureza:97.08%Cor e Forma:Orange SolidPeso molecular:565.493HMN-176
CAS:HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).Fórmula:C20H18N2O4SPureza:98.92% - 98.99%Cor e Forma:SolidPeso molecular:382.433Centrinone-B
CAS:Centrinone-B (LCR-323) is a Plk4 inhibitor with potential anticancer activity for the study of triple-negative breast cancer.Fórmula:C27H27F2N7O5S2Pureza:98.71%Cor e Forma:SolidPeso molecular:631.67
![5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE](https://static.cymitquimica.com/products/TM/thumb-webp/T8912.webp)
